Skip to content
About

A peptide companion that treats you like an adult.

Juno is the trustworthy, always-on companion that helps you understand, plan, dose, track, and learn from your peptide journey. With honest evidence, accurate math, and AI that helps you make sense of your own data.

We are independent. We are not a clinic, not a vendor, not a telehealth funnel. We do not sell peptides, and we will not gate our tools behind a prescription wall.

Editorial posture (non-negotiable)

  • Educational, not prescriptive. We surface what the literature says with citations and confidence levels. We never tell users what to do.
  • Honest about evidence quality. We tier every claim. GLP-1 agonists are Tier 1 RCT data. BPC-157 in humans is Tier 3 despite community enthusiasm. We do not soften tiers to make peptides look better than the data supports.
  • Encourage clinician involvement. Consistent nudge toward a knowledgeable provider and bloodwork. Framed as "how to do this responsibly," not as a gate.
  • No miracle claims. Mechanisms, study results, effect sizes, limitations. Never "burns fat" or "reverses aging."
  • Adult-to-adult. We acknowledge that many users are doing this without a prescriber. Our job is to make their decisions better-informed, not to pretend they don't exist.

How evidence tiers work

Every peptide entry is classified per peptide-indication pair. The same molecule can be Tier 1 for one use and Tier 4 for another. The classification follows a decision tree we apply identically to every peptide, regardless of how popular or marketed it is.

Tier 1
Established human evidence. Multiple well-designed RCTs (typically n>50 per arm), replicated by independent research groups, peer-reviewed, with effect size and safety profile reasonably characterized in humans.
Tier 2
Limited human evidence. Small RCTs, Phase 1/2 trials without Phase 3 follow-up, or multiple consistent observational studies. Mechanism plausible from animal/in-vitro work.
Tier 3
Animal / in-vitro only. Strong rodent or larger animal data; in-vitro mechanistic work; one or two isolated human case reports. This is where most "research peptides" actually live, despite community framing that often implies more.
Tier 4
Anecdotal / theoretical. No usable primary literature. Forum reports, podcast claims, marketing material only. Mechanism speculation without experimental support.

Bias toward the lower tier when uncertain. Editorial credibility comes from never overstating. The cost of one tier too low is "user reads more carefully." The cost of one tier too high is "user trusts a claim that doesn't hold up."

What's here today

  • Peptide library — eight seed entries spanning the evidence tiers, with citations, dose ranges, contraindications, and side effects.
  • Peptide calculator — full reconstitution math with edge-case warnings and an SVG syringe visualization. The math has comprehensive automated test coverage.
  • Reconstitution guide — an interactive walkthrough with sterile technique notes.
  • Flashcards — three beginner-mode decks (Recovery, Metabolic, Longevity) with SM-2 spaced repetition.

What's coming

Phase 2 brings auth, the regimen designer, dose logging, side-effect tracking, and the iOS app. Phase 3 brings biomarker trends, lab-PDF OCR, an AI cause-and-effect engine, and a doctor-ready summary generator. Phase 4 brings a vendor directory, the Android app, and network effects.

Get in touch

Found a stale citation? A tier that doesn't match the literature? A calculator edge case we didn't catch? Editorial corrections come fast. Reach us at hello@juno.coach.